Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 4Breast 4Thoracic 2Lymphoid 2Gynecologic 2CNS 2Other solid neoplasm 1Other hematologic neoplasm 1Head & Neck 1Endocrine 1

Conditions

Neoplasms 4Neoplasm Metastasis 3

Interventions

Surveys and Questionnaires 65pembrolizumab 56Gemcitabine 54Paclitaxel 51Blood Specimen Collection 45Carboplatin 44Bevacizumab 41Docetaxel 38Cisplatin 33Nivolumab 32Fluorouracil 31Capecitabine 28Radiotherapy 25Pemetrexed 25Irinotecan 25Standard of Care 24Interviews as Topic 24Magnetic Resonance Spectroscopy 23Leucovorin 22Erlotinib Hydrochloride 22atezolizumab 21Cetuximab 21Afatinib 21Oxaliplatin 19trametinib 18Exercise 18Ipilimumab 17Sorafenib 16Cyclophosphamide 16olaparib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neoplasms × ribociclib × Tumor-Agnostic × Clear all
NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

NCT02925234 2024-01-24

DRUP

The Netherlands Cancer Institute

Phase 2 Recruiting
1,550 enrolled
Tumor-Agnostic

Neoplasms

NCT04801966 2023-05-10

TAILOR

Peter MacCallum Cancer Centre, Australia

Phase NA Terminated
3 enrolled
Tumor-Agnostic

Neoplasms

NCT01898845 2020-12-19

A Phase I Study of LEE011 in Asian Patients

Novartis

Phase 1 Completed
17 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡